Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Diagnostic workup in front of an adult monocytosis.

Labrousse J, Pasini S, Vignon G, Bonnin A, Mottaz P, Carrere F, Augereau PF, Aucher P, Lellouche F.

Ann Biol Clin (Paris). 2019 Sep 4. doi: 10.1684/abc.2019.1475. [Epub ahead of print]

PMID:
31486402
2.

[Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks].

Babin M, Folliard C, Robert J, Sorrieul J, Kieffer H, Augereau P, Devys C.

Ann Pharm Fr. 2019 Sep;77(5):426-434. doi: 10.1016/j.pharma.2019.05.001. Epub 2019 Jul 7. French.

PMID:
31288930
3.

Benefits versus risk profile of buparlisib for the treatment of breast cancer.

Patsouris A, Augereau P, Frenel JS, Robert M, Gourmelon C, Bourbouloux E, Berton-Rigaud D, Chevalier LM, Campone M.

Expert Opin Drug Saf. 2019 Jul;18(7):553-562. doi: 10.1080/14740338.2019.1623877. Review.

PMID:
31159599
4.

Monoclonal gammopathy of undetermined significance (MGUS): interpretative shades of analysis and sometimes serious clinical consequences.

Carrère F, Plasse F, Pasini S, Vignon G, Mottaz P, Bonnin A, Augereau PF, Aucher P, Lellouche F.

Ann Biol Clin (Paris). 2019 Jun 1;77(3):245-254. doi: 10.1684/abc.2019.1440.

PMID:
31115338
5.

Pertuzumab for the treatment of breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Rev Anticancer Ther. 2019 Aug 29:1-11. doi: 10.1080/14737140.2019.1596805. [Epub ahead of print]

PMID:
30884986
6.

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):85-91. doi: 10.1080/17425255.2019.1559816. Epub 2019 Jan 5. Review.

PMID:
30577708
7.

Diagnostic workup in front of an adult neutropenia.

Bonnin A, Vignon G, Mottaz P, Labrousse J, Carrere F, Augereau PF, Aucher P, Lellouche F.

Ann Biol Clin (Paris). 2018 Dec 1;76(6):651-658. doi: 10.1684/abc.2018.1393. Review.

PMID:
30543190
8.

Emerging PARP inhibitors for treating breast cancer.

Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.

Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Review.

PMID:
30251552
9.

IgM Myeloma: case report and literature review.

Labrousse J, Plasse F, Aucher P, Augereau P, Bertin A, Carrere F, Cognée AS, Vignon G, Violette J, Lellouche F.

Ann Biol Clin (Paris). 2018 Oct 1;76(5):575-578. doi: 10.1684/abc.2018.1380. Review.

PMID:
30226197
10.

How I do in front of an hemolytic anemia of unknown etiology?

Vignon G, Jeanneau R, Labrousse J, Aubrit S, Mottaz P, Carrère F, Augereau PF, Aucher P, Lellouche F.

Ann Biol Clin (Paris). 2018 Oct 1;76(5):493-503. doi: 10.1684/abc.2018.1381. Review.

PMID:
30226192
11.

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M.

Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9. Review.

PMID:
30143968
12.

Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.

Guillemois S, Patsouris A, Peyraga G, Chassain K, Le Corre Y, Campone M, Augereau P.

Clin Breast Cancer. 2018 Oct;18(5):e755-e758. doi: 10.1016/j.clbc.2018.07.006. Epub 2018 Aug 16. No abstract available.

PMID:
30120047
13.

[Diagnostic workup in front of an atypical non hemolytic anemia].

Colin JY, Vignon G, Mottaz P, Labrousse J, Carrere F, Augereau PF, Aucher P, Lellouche F.

Rev Med Interne. 2018 Nov;39(11):855-862. doi: 10.1016/j.revmed.2018.03.382. Epub 2018 Apr 13. Review. French.

PMID:
29661593
14.

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS.

Breast Cancer Res Treat. 2018 Apr;168(2):559-566. doi: 10.1007/s10549-017-4623-8. Epub 2017 Dec 15.

PMID:
29247442
15.

Efficacy of buparlisib in treating breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1.

PMID:
29169282
16.

A new case of IgE multiple myeloma with review of literature.

Vignon G, Cognée AS, Carrere F, Masson I, Borde F, Augereau PF, Aucher P, Lellouche F.

Ann Biol Clin (Paris). 2017 Aug 1;75(4):442-444. doi: 10.1684/abc.2017.1263. Review.

PMID:
28751289
17.

[Two cases of myeloid sarcomas with review of literature].

Mottaz P, Becot-Bretez F, Jeanneau R, Vignon G, Bertin A, Carrere F, Augereau PF, Aucher P, Lellouche F.

Rev Med Interne. 2017 Nov;38(11):774-777. doi: 10.1016/j.revmed.2017.06.002. Epub 2017 Jun 28. Review. French.

PMID:
28668372
18.

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M.

Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Review.

19.

Olaparib for the treatment of breast cancer.

Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.

Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Review.

PMID:
28395540
20.

Vinflunine for the treatment of breast cancer.

Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M.

Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Review.

PMID:
27484180
21.

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, Rey A, Balleyguier C, Tazi Y, Leary A, Augereau P, Morice P, Droz JP, Fizazi K, Lhommé C.

Eur J Cancer. 2014 Aug;50(12):2082-9. doi: 10.1016/j.ejca.2014.05.002. Epub 2014 Jun 5.

PMID:
24910417
22.

Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.

Linot B, Augereau P, Breheret R, Laccourreye L, Capitain O.

Support Care Cancer. 2014 Oct;22(10):2831-7. doi: 10.1007/s00520-014-2270-8. Epub 2014 May 13.

PMID:
24821366
23.

Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study.

Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, Capitain O.

J Neurooncol. 2014 Apr;117(2):253-9. doi: 10.1007/s11060-014-1378-5. Epub 2014 Jan 31.

PMID:
24481998
24.

[Differential diagnosis of local tumor recurrence or radionecrosis after stereotactic radiosurgery for treatment of brain metastasis].

Patsouris A, Augereau P, Tanguy JY, Morel O, Menei P, Rousseau A, Paumier A.

Cancer Radiother. 2014 Mar;18(2):142-6. doi: 10.1016/j.canrad.2013.10.013. Epub 2014 Jan 13. French.

PMID:
24433952
25.

High pain catastrophizing scores in one-fourth of patients on biotherapy for spondylarthritis or rheumatoid arthritis.

Penhoat M, Saraux A, Le Goff B, Augereau P, Maugars Y, Berthelot JM.

Joint Bone Spine. 2014 May;81(3):235-9. doi: 10.1016/j.jbspin.2013.10.004. Epub 2013 Dec 8.

PMID:
24321439
26.

The RIP140 gene is a transcriptional target of E2F1.

Docquier A, Augereau P, Lapierre M, Harmand PO, Badia E, Annicotte JS, Fajas L, Cavaillès V.

PLoS One. 2012;7(5):e35839. doi: 10.1371/journal.pone.0035839. Epub 2012 May 18.

27.

Regulation of hormone signaling by nuclear receptor interacting proteins.

Duong V, Augereau P, Badia E, Jalaguier S, Cavailles V.

Adv Exp Med Biol. 2008;617:121-7. doi: 10.1007/978-0-387-69080-3_11. Review. No abstract available.

28.

The nuclear receptor transcriptional coregulator RIP140.

Augereau P, Badia E, Carascossa S, Castet A, Fritsch S, Harmand PO, Jalaguier S, Cavaillès V.

Nucl Recept Signal. 2006 Oct 30;4:e024.

29.

Negative regulation of hormone signaling by RIP140.

Augereau P, Badia E, Balaguer P, Carascossa S, Castet A, Jalaguier S, Cavaillès V.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):51-9. Epub 2006 Oct 23. Review.

PMID:
17056252
30.

Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling.

Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, Balaguer P, Cavailles V.

Mol Pharmacol. 2006 Apr;69(4):1338-46. Epub 2006 Jan 3.

PMID:
16391242
31.

[RIP140 and hormone signaling].

Castet A, Carascossa S, Duong V, Augereau P, Jalaguier S, Cavaillès V.

Med Sci (Paris). 2005 Mar;21(3):273-8. Review. French.

32.

Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition.

Castet A, Boulahtouf A, Versini G, Bonnet S, Augereau P, Vignon F, Khochbin S, Jalaguier S, Cavaillès V.

Nucleic Acids Res. 2004 Apr 1;32(6):1957-66. Print 2004.

33.

[About a neonatal myelomonocytic leukemia].

Augereau PF, Ansoborlo S, Aucher P.

Ann Biol Clin (Paris). 2002 Nov-Dec;60(6):715-8. French. No abstract available.

34.

[Effectiveness of postoperative drainage after bipolar sealed endoprosthetic arthroplasty for femur neck fracture. Results of a prospective randomized study of 86 cases].

Duranthon LD, Grimberg J, Vandenbussche E, Mondoloni B, Augereau P.

Rev Chir Orthop Reparatrice Appar Mot. 2000 Jun;86(4):370-2. French. No abstract available.

PMID:
10880936
35.

Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines.

Giamarchi C, Solanas M, Chailleux C, Augereau P, Vignon F, Rochefort H, Richard-Foy H.

Oncogene. 1999 Jan 14;18(2):533-41.

36.

Retinoid regulation of human cathepsin D gene expression.

Sheikh MS, Augereau P, Chalbos D, Garcia M, Rochefort H.

J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):283-91.

PMID:
8639464
37.

Insensitivity of cathepsin D gene to estradiol in endometrial cells is determined by the sequence of its estrogen responsive element.

Miralles F, Gaudelet C, Cavailles V, Rochefort H, Augereau P.

Biochem Biophys Res Commun. 1994 Aug 30;203(1):711-8.

PMID:
8074726
38.

Characterization of the proximal estrogen-responsive element of human cathepsin D gene.

Augereau P, Miralles F, Cavaillès V, Gaudelet C, Parker M, Rochefort H.

Mol Endocrinol. 1994 Jun;8(6):693-703.

PMID:
7935485
39.

Reassessment of breakpoints in chromosome 11p15.

Henry I, van Heyningen V, Puech A, Scrable H, Augereau P, Boehm T, Rabbitts T, Mannens M, Rochefort H, Jones C, et al.

Cytogenet Cell Genet. 1993;62(1):52-3.

PMID:
8422757
40.
41.

A magnetically actuated left ventricular assist device.

Kovacs SG, Reynolds DG, McKeown PP, Augereau PG, Wasselle JA, Ondrovic LE, Aiba M.

ASAIO J. 1992 Jan-Mar;38(1):38-46.

PMID:
1348192
42.

Cathepsin D gene of human MCF7 cells contains estrogen-responsive sequences in its 5' proximal flanking region.

Cavailles V, Augereau P, Rochefort H.

Biochem Biophys Res Commun. 1991 Jan 31;174(2):816-24.

PMID:
1993074
43.

Regulation, clinical and biological significance of cathepsin D in breast cancer.

García M, Augereau P, Briozzo P, Capony F, Cavailles V, Freiss G, Maudelonde T, Montcourrier P, Vignon F, Rochefort H.

Rev Esp Fisiol. 1990 Mar;46(1):39-41. Review.

PMID:
2204091
44.

A hormone-regulated pro-cathepsin D secreted by human mammary cancer cells.

Capony F, Garcia M, Montcourrier P, Cavailles V, Augereau P, Briozzo P, Vignon F, Rochefort H.

Biochem Soc Trans. 1989 Feb;17(1):31-3. No abstract available.

PMID:
2714515
45.

Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer.

Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I, Garcia M.

J Steroid Biochem. 1989;34(1-6):177-82.

PMID:
2626016
46.

Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells.

Rochefort H, Augereau P, Briozzo P, Capony F, Cavailles V, Freiss G, Garcia M, Maudelonde T, Morisset M, Vignon F.

Biochimie. 1988 Jul;70(7):943-9.

PMID:
3145027
47.

Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Cavailles V, Augereau P, Garcia M, Rochefort H.

Nucleic Acids Res. 1988 Mar 25;16(5):1903-19.

48.

Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11.

Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Derocq D, Capony F, Ferrara P, Rochefort H.

Mol Endocrinol. 1988 Feb;2(2):186-92.

PMID:
3398849
49.

The 52K cathepsin-D of breast cancer: structure, regulation, function and clinical value.

Rochefort H, Augereau P, Capony F, Garcia M, Cavailles V, Freiss G, Morisset M, Vignon F.

Cancer Treat Res. 1988;40:207-21. Review. No abstract available.

PMID:
2908651
50.

The estrogen-regulated 52K-cathepsin-D in breast cancer: from biology to clinical applications.

Rochefort H, Capony F, Augereau P, Cavailles V, Garcia M, Morisset M, Freiss G, Maudelonde T, Vignon F.

Int J Rad Appl Instrum B. 1987;14(4):377-84.

PMID:
3654255

Supplemental Content

Loading ...
Support Center